| Symbol | CRIS |
|---|---|
| Name | CURIS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 128 SPRING STREET, LEXINGTON, MA 02421 |
| Telephone | 617-503-6500 |
| Fax | — |
| — | |
| Website | https://www.curis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001108205 |
| Description | Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. Additional info from NASDAQ: |
2026-07-25 01:54
NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read more
2026-07-25 01:36
NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read more
2026-07-01 12:23
New Form 8-K/A - CURIS INC <b>Filed:</b> 2026-07-01 <b>AccNo:</b> 0001108205-26-000076 <b>Size:</b> 147 KB <br />Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07271667 | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in… | Phase2 | Chronic Lymphocytic Leukemia | Recruiting | 2026-04-23 | 2027-11-01 | ClinicalTrials.gov |
| NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvaluma… | Phase1 | Metastatic Biliary Tract Cancer | Recruiting | 2026-03-27 | 2032-05-31 | ClinicalTrials.gov |
| NCT05187182 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated… | Phase1 | Gastric Cancer | Recruiting | 2023-06-02 | 2029-04-30 | ClinicalTrials.gov |
| NCT05178342 | Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelody… | Phase2 | Myelodysplastic Syndromes | Terminated | 2022-01-01 | 2024-07-31 | ClinicalTrials.gov |
| NCT04475523 | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tu… | Phase1 | Solid Tumor | Completed | 2020-09-22 | 2023-05-19 | ClinicalTrials.gov |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acu… | Phase1 | Acute Myelogenous Leukemia | Suspended | 2020-07-06 | 2026-04-01 | ClinicalTrials.gov |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults | Early_Phase1 | Diffuse Intrinsic Pontine Glioma | Active_Not_Recruiting | 2019-08-07 | 2027-08-31 | ClinicalTrials.gov |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA… | Phase1 | Relapsed Hematologic Malignancy | Recruiting | 2017-12-28 | 2026-10-01 | ClinicalTrials.gov |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Soli… | Phase1 | Lymphoma | Completed | 2016-10-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT02674750 | Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL… | Phase2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Completed | 2016-07-01 | 2019-05-28 | ClinicalTrials.gov |
| NCT02812875 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patien… | Phase1 | Advanced Solid Tumors or Lymphomas | Completed | 2016-05-01 | 2020-05-07 | ClinicalTrials.gov |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacok… | Phase1 | Triple-Negative Breast Cancer | Completed | 2014-11-01 | 2019-05-31 | ClinicalTrials.gov |
| NCT01908413 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-4… | Phase1 | Lymphoma | Terminated | 2013-07-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (… | Phase1 | Lymphoma | Completed | 2012-12-01 | 2020-10-09 | ClinicalTrials.gov |
| NCT01702285 | Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orall… | Phase1 | Cancer | Terminated | 2012-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01384799 | Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & … | Phase1 | Head and Neck Cancer | Completed | 2011-11-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01171924 | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokine… | Phase1 | Head and Neck Cancer | Completed | 2010-07-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00728793 | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUD… | Phase1 | Tumors | Completed | 2008-08-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00004487 | Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients Wi… | Phase3 | Vesicoureteral Reflux | Unknown | 1999-05-01 | — | ClinicalTrials.gov |
Total clinical trials: 19
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Zanubrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Emavusertib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Zanubrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Emavusertib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Zanubrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Emavusertib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Zanubrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Emavusertib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Zanubrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Emavusertib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Zanubrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Emavusertib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| CUDC-101 | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01171924 |
| CUDC-427 | Other | Phase PHASE1 | Lymphoma | TERMINATED | NCT01908413 |
| CUDC-101 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT01702285 |
| Radiation Therapy | Drug | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01384799 |
| Cisplatin | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01384799 |
| CUDC-101 | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01384799 |
| CUDC-907 | Other | Phase PHASE1 | Triple-Negative Breast Cancer | COMPLETED | NCT02307240 |
| CA-170 | Other | Phase PHASE1 | Advanced Solid Tumors or Lymphomas | COMPLETED | NCT02812875 |
| venetoclax | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01742988 |
| Rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01742988 |
| fimepinostat | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01742988 |
| CUDC-907 | Other | Phase PHASE2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | COMPLETED | NCT02674750 |
| CI-8993 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04475523 |
| CA-4948 | Other | Phase PHASE2 | Myelodysplastic Syndromes | TERMINATED | NCT05178342 |
| Therapeutic Conventional Surgery | Procedure | Phase EARLY_PHASE1 | Diffuse Intrinsic Pontine Glioma | ACTIVE_NOT_RECRUITING | NCT03893487 |
| Fimepinostat | Other | Phase EARLY_PHASE1 | Diffuse Intrinsic Pontine Glioma | ACTIVE_NOT_RECRUITING | NCT03893487 |
| CUDC-907 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT02909777 |
| Venetoclax | Other | Phase PHASE1 | Acute Myelogenous Leukemia | SUSPENDED | NCT04278768 |
| Emavusertib | Other | Phase PHASE1 | Acute Myelogenous Leukemia | SUSPENDED | NCT04278768 |
| Zanubrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Emavusertib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Durvalumab | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT07107750 |
| Cisplatin | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT07107750 |
| Gemcitabine | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT07107750 |
| Emavusertib | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT07107750 |
| Ibrutinib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Emavusertib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| mFOLFOX7 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Ibrutinib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Emavusertib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Ibrutinib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Emavusertib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Ibrutinib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Emavusertib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Ibrutinib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Emavusertib | Other | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Zanubrutinib | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| Durvalumab | BIOLOGICAL | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT07107750 |
| Gemcitabine | DRUG | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT07107750 |
| mFOLFOX7 | DRUG | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Trastuzumab | DRUG | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CA-4948 | DRUG | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05187182 |
| CI-8993 | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04475523 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myelogenous Leukemia | SUSPENDED | NCT04278768 |
| Therapeutic Conventional Surgery | PROCEDURE | Phase EARLY_PHASE1 | Diffuse Intrinsic Pontine Glioma | ACTIVE_NOT_RECRUITING | NCT03893487 |
| Fimepinostat | DRUG | Phase EARLY_PHASE1 | Diffuse Intrinsic Pontine Glioma | ACTIVE_NOT_RECRUITING | NCT03893487 |
| Ibrutinib | DRUG | Phase PHASE1 | Relapsed Hematologic Malignancy | RECRUITING | NCT03328078 |
| Emavusertib | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | RECRUITING | NCT07271667 |
| CA-170 | DRUG | Phase PHASE1 | Advanced Solid Tumors or Lymphomas | COMPLETED | NCT02812875 |
| CUDC-907 | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT02909777 |
| Radiation Therapy | RADIATION | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01384799 |
| Cisplatin | DRUG | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT07107750 |
| CUDC-427 | DRUG | Phase PHASE1 | Lymphoma | TERMINATED | NCT01908413 |
| venetoclax | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT01742988 |
| Rituximab | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT01742988 |
| fimepinostat | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT01742988 |
| CUDC-101 | DRUG | Phase PHASE1 | Cancer | TERMINATED | NCT01702285 |
| chondrocyte-alginate gel suspension | DRUG | Phase PHASE3 | Vesicoureteral Reflux | UNKNOWN | NCT00004487 |
Total products: 111